Compass Pathways gains Stifel’s Buy rating as its COMP360 psilocybin treatment advances in Phase 3 trials. Key depression study data expected in 2025-2026.
Latest Ratings for CMPS
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 2021 | HC Wainwright & Co. | Maintains | Buy | |
| Oct 2021 | Oppenheimer | Initiates Coverage On | Outperform | |
| Jul 2021 | Citigroup | Initiates Coverage On | Buy |
